This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Metachromatic leukodystrophy panel [3 genes]
Metachromatic leukodystrophy is an autosomal recessive metabolic hereditary disease characterized by the accumulation of sulfatides in various tissues, which produces progressive demyelination in the central and peripheral nervous systems and progressive decline in motor and cognitive functions.
In most cases, this disease is caused by a deficiency of the arylsulfatase A enzyme, encoded by the ARSA gene, giving rise to the accumulation of 3′-O-sulfogalactosylceramide (sulfatide) in oligodendrocytes, Schwann cells, and some neurons. Also, some pathogenic variants resulting in saposin B deficiency have been identified in the gene that encodes prosaposin (PSAP), which is involved in the lysosomal hydrolisis of sphingolipids. Finally, homozygous pathogenic variants in the SUMF1 gene (which encodes an enzyme necessary for post-translational modification and catalytic activation of sulfatases) give rise to multiple sulfatase deficiency, which is characterized by the accumulation of sulfates, sulfated glycosaminoglycans, sphingolipids and steroid sulfates, and which combines the characteristics of metachromatic leukodystrophy and various mucopolysaccharidoses.
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Metachromatic leukodystrophy panel
Turnaround time (TAT): 6 weeks
Ref. S-202008606
- ARSA
- PSAP
- SUMF1
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.